Dr. Clay Siegall is the co-founder, CEO, Chairman of the Board of Directors, and president of Seattle Genetics. The company was founded in 1998 to come up with a solution on antibody-based cancer treatments. In 2011, their drug ADCETRIS was approved by the FDA for use. Dr. Siegall has been instrumental in the raising of capital for various activities. In 2001, he managed to raise $675 million through an initial public offering, private and public financing. Dr. Siegell holds a Ph.D. holder in the field of Genetics from George Washington University. He also holds a B.S. from the University of Maryland in the field of Zoology.
Dr. Siegell has worked with various pharmaceutical companies. He serves on the Board of Directors at the Alder BioPharmaceuticals. He worked with Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. He has also served with the National Cancer Institute, National Institutes of Health between 1988 and 1991. Dr. Siegall is has authored over 70 publications.
At the Seattle Genetics headquarters at the Bothell Cascade Business Park, a model of the human antibody is presented in Lego bricks. This portrays their commitment to their studying on human antibodies. Seattle Genetics believes that the same way the Lego Bricks connect with each other to create an antibody model, it’s the same way they study, manipulate and finally package the ultimate drugs to boost the antibodies that fight the cancer cell from the inside.
Seattle Genetics is valued at about $10 billion. The company consists of 900 employees. It is considered as the largest biotech company in Washington. The company heavily invests in research and marketing of their products. Its aim is to become a big pharmaceutical company. This year alone, the company expects to grow their workforce by over 200 employees.
Adcetris is currently the company’s main drug when it comes to treating Hodgkin lymphoma, a type of cancer that is associated with the lymph system and is known to spread to other parts of the body. Once the testing period is over and the drug has been proven to be successful, sales should commence. Seattle Genetics has a number of drugs that are currently in production. This is a clear indication of Clay Siegall’s desire for steering the company to greatness instead of selling to a larger company, the way other biotech companies are doing. Clay Siegall is aimed at growing Seattle Genetics to an international company. This is evident by the company’s focus on developing drugs that are internationally marketed.